LG Electronics Posts Record Q1 Revenue Amid Strong Demand and Cost Improvements 
Nike Beats Q3 Estimates but China Weakness and Margin Pressure Weigh on Outlook 
SoftwareONE Posts 22.5% Revenue Surge in 2025 on Crayon Acquisition 
Norma Group Posts Revenue Decline in 2025, Eyes Modest Recovery in 2026 
Samsung Electronics Eyes Record Q1 Profit Amid AI-Driven Chip Boom 
UPS and Teamsters Reach Agreement to Limit Driver Severance Program 
Paramount Skydance Secures $24B from Gulf Sovereign Wealth Funds for Warner Bros. Discovery Takeover 
First Western Ship Transits Strait of Hormuz Since Iran War Began 
Pershing Square Bids €30.40 Per Share to Acquire Universal Music Group in $9.4B Deal 
OpenAI Executive Shake-Up Ahead of Anticipated 2026 IPO 
UAE's Largest Natural Gas Facility Suspended After Attack-Triggered Fire 
Apple's Foldable iPhone Faces Engineering Setbacks, Mass Production Timeline at Risk 
Annie Altman Amends Sexual Abuse Lawsuit Against OpenAI CEO Sam Altman 
Microsoft Eyes $7B Texas Energy Deal to Power AI Data Centers 
TSMC Japan's Second Fab to Produce 3nm Chips by 2028 
MATCH Act Targets ASML and Chinese Chipmakers in New U.S. Export Crackdown 
Microsoft's $10 Billion Japan Investment: AI Infrastructure and Data Sovereignty Push 
NEW YORK, July 25, 2017 -- The Law Offices of Vincent Wong announce that a class action lawsuit has been commenced in District of New Jersey on behalf of investors who purchased Sinovac Biotech Ltd. ("Sinovac Biotech Ltd.") (NASDAQ:SVA) securities between April 30, 2013 and May 16, 2017.
Click here to learn about the case: http://www.wongesq.com/pslra-sb/sinovac-biotech-ltd?wire=3. There is no cost or obligation to you.
According to the complaint, throughout the Class Period, the Company issued materially false and misleading statements and/or failed to disclose that: (1) Defendant Weidong Yin, Sinovac’s Chairman and CEO, bribed a member of the Chinese Food and Drug Administration to assist Sinovac’s vaccine clinical trial and approval; (2) Yin's conduct would subject Sinovac to heightened regulatory scrutiny; and (3) subsequently, Sinovac’s public statements were materially false and misleading at all relevant times.
If you suffered a loss in Sinovac Biotech Ltd. you have until September 1, 2017 to request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn’t require that you serve as a lead plaintiff. To obtain additional information, contact Vincent Wong, Esq. either via email at [email protected], by telephone at 212.425.1140, or visit http://www.wongesq.com/pslra-sb/sinovac-biotech-ltd?wire=3.
Vincent Wong, Esq. is an experienced attorney that has represented investors in securities litigations involving financial fraud and violations of shareholder rights. Attorney advertising. Prior results do not guarantee similar outcomes.
CONTACT: Vincent Wong, Esq. 39 East Broadway Suite 304 New York, NY 10002 Tel. 212.425.1140 Fax. 866.699.3880 E-Mail: [email protected]
